Solventum Corporation
NYSE:SOLVMedical - Care Facilities
-$2.00 today
- Market cap
- $14.70B
- Beta
- 0.75
- P/E (TTM)
- 9.1
- EPS (TTM)
- $8.22
Volume 0.76M
Average 1.70M
SOLV Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Solventum CorporationNYSE: SOLV
Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Free cash flow growth accelerates
Q2 FY2026 free cash flow of $144M rose 144.1% year over year, ahead of the -180.3% change in trailing-twelve-month free cash flow.
Context
- Free cash flow amounted to 0.1% of revenue in FY2025, down 9.6 pp from a year earlier.
- Free cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +144.1% holds above the trailing-twelve-month pace of -180.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (10M) USD
- Year-over-year change
- -101.2%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10M) | -101.2% |
| FY2024 | 2024-12-31 | 805M | -50.5% |
| FY2023 | 2023-12-31 | 1.63B | +13.8% |
| FY2022 | 2022-12-31 | 1.43B | -25.8% |
| FY2021 | 2021-12-31 | 1.93B | — |
Free Cash Flow vs competitors
How SOLV compares with its peers on the latest reported figures
- SOLV's LTM Jun 2026 free cash flow of $118M is the 8th largest of the 10 companies compared; the peer median is $252.22M.
- Its year-over-year change of -180.3% is the lowest of 10, against a peer median of +5.2%.
- Free cash flow amounts to 1.4% of revenue for SOLV, versus a peer median of 8.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.81B | +5.2% | +11.5% | 13.9% | |
| LTM Jun 2026 | $678M | +103.6% | -17.5% | 5.9% | |
| LTM Jul 2026 | $678M | +64.6% | -1.3% | 16.0% | |
| LTM Jun 2026 | $539M | +50.6% | +4.2% | 4.0% | |
| LTM Sep 2026 | $252.22M | +5.1% | +45.3% | 15.7% | |
| LTM Oct 2026 | $242M | -7.8% | +29.1% | 8.4% | |
| LTM Jun 2026 | $152.83M | +150.3% | — | 7.1% | |
| LTM Jun 2026 | $118M | -180.3% | — | 1.4% | |
| LTM Mar 2026 | $104M | -62.6% | -34.4% | 2.8% | |
| LTM Mar 2026 | $13.02M | -6.0% | -11.0% | 34.7% | |
| Peer median (excluding SOLV) | $252.22M | +5.2% | +1.5% | 8.4% | |
Competitors are the stored peer set for SOLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.46B | 1.34B | 1.35B | 479M | 1.56B |
| Depreciation & Amortization | 597M | 578M | 561M | 555M | 489M |
| Deferred Income Tax | (34M) | (141M) | (142M) | (155M) | (120M) |
| Stock-Based Compensation | 38M | 37M | 39M | 112M | 161M |
| Change in Working Capital | 67M | (202M) | 126M | 160M | (119M) |
| Accounts Receivables | (1M) | (32M) | (129M) | 276M | 78M |
| Inventory | (136M) | (82M) | 23M | (132M) | (139M) |
| Accounts Payables | 68M | 25M | 105M | 266M | 104M |
| Other Working Capital | 136M | (113M) | 127M | (250M) | (162M) |
| Other Non-Cash Items | 74M | 64M | (15M) | 34M | (1.6B) |
| Operating Cash Flow | 2.2B | 1.68B | 1.92B | 1.19B | 369M |
| Capital Expenditures | (277M) | (251M) | (290M) | (380M) | (379M) |
| Acquisitions (Net) | 0 | 0 | 60M | 0 | (696M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (1M) | (2M) | 0 | 0 | 3.87B |
| Investing Cash Flow | (278M) | (253M) | (230M) | (380M) | 2.8B |
| Debt Repayment | 0 | 0 | 0 | 8B | (3.07B) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.96B) | (1.46B) | (1.55B) | (8.24B) | 13M |
| Financing Cash Flow | (1.96B) | (1.46B) | (1.55B) | (240M) | (3.06B) |
| Effect of Forex Changes | 3M | 4M | 0 | 3M | 7M |
| Net Change in Cash | (33M) | (30M) | 133M | 568M | 116M |
| Free Cash Flow | 1.93B | 1.43B | 1.63B | 805M | (10M) |
Solventum Corporation
NYSE:SOLV
Intrinsic Alpha fair value
Locked
Current Price
$86.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.